Institutional investors and pension funds are finally figuring out that environmental, social and governance (ESG) investing is more than merely a fad. Mary Jane McQuillen, Head of ESG Investment at ClearBridge Investments, said the millennial generation didn’t need nearly as long to be convinced. 'On the retail side, more and more individuals and in particular the millennials, have been asking about ESG. They very much get it so they don’t have to have the performance factor proven for them. They understand it,' said McQuillen. As for ClearBridge’s approach to ESG investing, McQuillen said the firm addresses each selection on a fundamental level, sector by sector. 'There is some negative screening in the sense that there are certain industries that our clients prefer not to invest in, like tobacco for example,' said McQuillen. 'But it is also very much an integration of the value chain. In other words, where are the opportunities? Where are the risks? Our fundamental analysts at the sector level have identified the ESG issues and they weight it by sector because we understand that the issues that affect the technology company might not be the same effect in an energy company or consumer staples company.'
More from Video
Amid the Selling, Here's the Big Question Now
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
One Tweet Pulls the Rug Out From Under the Indexes
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
A Technical Look at the New Dow Jones Industrial Average
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
Conagra Brands Looks Tastier After Its Upgrade to Buy
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts
Breaking down an approach to the long side of this biotech stock.